Imagion Biosystems Limited (IBL), an Australian medical device company, is developing a new non-invasive cancer detection technology. Unlike existing medical imaging technologies that identify a “region of interest” IBL’s MagSense™ technology has the potential to provide non-invasive, molecularly specific, detection of cancerous tumors. It will be the first new form of medical imaging in more than 50 years. The diagnostic imaging technology is based on the principles of Superparamagnetic Relaxometry (SPMR) and includes a detection instrument system and a injectable tracer which is a cancer-specific nanoparticle test reagent. The test reagent is administered to the patent before measurement, e.g. via intravenous or subcutaneous injection, and the bio-functionalized nanoparticles target and bind to the cancer cells and are detectable by the instrument. The technology is not restricted to diagnosis or detection of one kind of cancer but is broadly applicable for detecting a many solid tumors and will be more sensitive than current imaging technologies.,Imagion Biosystems Limited (IBL), an Australian medical device company, is developing a new non-invasive cancer detection technology. Unlike existing medical imaging technologies that identify a “region of interest” IBL’s MagSense™ technology has the potential to provide non-invasive, molecularly specific, detection of cancerous tumors. It will be the first new form of medical imaging in more than 50 years. The diagnostic imaging technology is based on the principles of Superparamagnetic Relaxometry (SPMR) and includes a detection instrument system and a injectable tracer which is a cancer-specific nanoparticle test reagent. The test reagent is administered to the patent before measurement, e.g. via intravenous or subcutaneous injection, and the bio-functionalized nanoparticles target and bind to the cancer cells and are detectable by the instrument. The technology is not restricted to diagnosis or detection of one kind of cancer but is broadly applicable for detecting a many solid tumors and will be more sensitive than current imaging technologies.